Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06909201 · ClinicalTrials.gov registry record
Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 70
- Enrollment target
NCT06909201: Recruiting study, sponsored by M.D. Anderson Cancer Center.
NCT06909201 is a clinical trial that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06909201 is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational.
Interventions
- DRUG HP 129Xe MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2030-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06909201
The ClinicalTrials.gov registry entry for NCT06909201 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HP 129Xe MRI is the first listed.
NCT06909201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06909201 about?
NCT06909201 is a clinical study titled "Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity". The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has no...
What is the current status of trial NCT06909201?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2026-03-31. Estimated completion is 2030-09-01.
What interventions are being tested in trial NCT06909201?
The interventions under investigation include: HP 129Xe MRI (DRUG).
Who is sponsoring clinical trial NCT06909201?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.